Spero Therapeutics Inc (SPRO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $58.26M
Last updated: Nov 17, 2026 at 11:05 AM ET
Spero Therapeutics Inc (SPRO) Earnings: Report Dates and Results
Spero Therapeutics (SPRO) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, Spero Therapeutics reported EPS of -$0.16, below the -$0.14 estimate. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SPRO has an expected report date of Mar 24, 2027.
SPRO Earnings Call
The latest SPRO earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 32 quarters below that had an estimate, SPRO beat 21 and missed 11. The widest gap in the table came in the quarter ended Mar 31, 2024, when EPS landed 300.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.16 | -$0.14 | -$0.14 - -$0.14 | -14.29% | Miss | N/A | 1 | 1 up, 0 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.16 | -$0.19 | N/A | +15.79% | Beat | N/A | N/A | N/A | Aug 12, 2026 | N/A |
| Mar 31, 2026 | -$0.13 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 13, 2026 | $258000 |
| Dec 31, 2025 | $0.53 | -$0.20 | -$0.20 - -$0.20 | N/A | N/A | N/A | 1 | 1 up, 0 down | Mar 26, 2026 | $41.30M |
| Sep 30, 2025 | -$0.13 | -$0.25 | -$0.25 - -$0.25 | +48.00% | Beat | N/A | 1 | 1 up, 0 down | Nov 13, 2025 | $5.44M |
| Jun 30, 2025 | -$0.03 | -$0.38 | N/A | +92.11% | Beat | N/A | 1 | 1 up, 0 down | Aug 12, 2025 | $14.19M |
| Mar 31, 2025 | -$0.25 | -$0.44 | N/A | +43.18% | Beat | N/A | 1 | 0 up, 1 down | May 13, 2025 | $5.87M |
| Dec 31, 2024 | -$0.37 | -$0.31 | -$0.35 - -$0.27 | -18.35% | Miss | -138.2% | 2 | 2 up, 1 down | Mar 27, 2025 | $15.04M |
| Sep 30, 2024 | -$0.32 | -$0.36 | -$0.56 - $0.02 | +11.11% | Beat | -900.0% | 3 | 1 up, 0 down | Nov 14, 2024 | $13.47M |
| Jun 30, 2024 | -$0.33 | -$0.38 | -$0.45 - -$0.25 | +13.16% | Beat | N/A | 3 | 0 up, 0 down | Aug 5, 2024 | $10.20M |
| Mar 31, 2024 | -$0.24 | -$0.06 | -$0.12 - $0.00 | -300.00% | Miss | N/A | 3 | 0 up, 0 down | May 15, 2024 | $9.27M |
| Dec 31, 2023 | $0.96 | -$0.10 | -$0.29 - $0.05 | N/A | N/A | +74.5% | 3 | 0 up, 0 down | Mar 13, 2024 | $73.52M |
| Sep 30, 2023 | $0.04 | -$0.03 | -$0.24 - $0.21 | +233.33% | Beat | N/A | 3 | 1 up, 0 down | Nov 13, 2023 | $25.47M |
| Jun 30, 2023 | -$0.23 | -$0.37 | -$0.46 - -$0.28 | +37.84% | Beat | N/A | 3 | 1 up, 0 down | Aug 10, 2023 | $2.72M |
| Mar 31, 2023 | -$0.25 | -$0.26 | -$0.43 - -$0.26 | +3.85% | Beat | N/A | 3 | 0 up, 0 down | May 11, 2023 | $2.07M |
| Dec 31, 2022 | $0.55 | $0.04 | -$0.40 - $0.87 | N/A | N/A | N/A | 3 | 0 up, 0 down | Mar 30, 2023 | $47.44M |
| Sep 30, 2022 | -$0.33 | -$0.24 | -$0.43 - -$0.23 | -37.50% | Miss | N/A | 3 | 0 up, 0 down | Nov 14, 2022 | $2.01M |
| Jun 30, 2022 | -$0.43 | -$0.93 | N/A | +53.76% | Beat | N/A | N/A | 0 up, 0 down | Aug 10, 2022 | $1.99M |
| Mar 31, 2022 | -$1.01 | -$0.95 | -$1.00 - -$0.80 | -6.32% | Miss | N/A | 3 | 1 up, 0 down | May 16, 2022 | $2.07M |
| Dec 31, 2021 | -$0.90 | -$0.75 | -$0.81 - -$0.61 | -20.00% | Miss | N/A | 4 | 0 up, 0 down | Mar 31, 2022 | $2.74M |
| Sep 30, 2021 | -$0.70 | -$0.66 | -$0.70 - -$0.60 | -6.06% | Miss | N/A | 3 | N/A | Nov 10, 2021 | $3.06M |
| Jun 30, 2021 | -$0.63 | -$0.75 | -$0.81 - -$0.69 | +16.00% | Beat | N/A | 4 | N/A | Aug 5, 2021 | $5.15M |
| Mar 31, 2021 | -$0.66 | -$0.63 | -$0.74 - -$0.54 | -4.76% | Miss | N/A | 4 | N/A | May 6, 2021 | $7.30M |
| Dec 31, 2020 | -$0.68 | -$0.74 | -$0.97 - -$0.63 | +8.11% | Beat | N/A | 5 | N/A | Mar 11, 2021 | $1.91M |
| Sep 30, 2020 | -$0.86 | -$0.89 | -$1.02 - -$0.76 | +3.37% | Beat | N/A | 6 | N/A | Nov 5, 2020 | $4.00M |
| Jun 30, 2020 | -$0.85 | -$1.13 | -$1.37 - -$0.95 | +24.78% | Beat | N/A | 6 | N/A | Aug 6, 2020 | $1.73M |
| Mar 31, 2020 | -$1.19 | -$1.25 | -$1.47 - -$0.74 | +4.80% | Beat | N/A | 6 | N/A | May 8, 2020 | $1.70M |
| Dec 31, 2019 | -$1.36 | -$1.08 | -$1.23 - -$0.92 | -25.93% | Miss | N/A | 6 | N/A | Mar 16, 2020 | $3.85M |
| Sep 30, 2019 | -$0.95 | -$0.85 | -$1.09 - -$0.70 | -11.76% | Miss | N/A | 6 | N/A | Nov 4, 2019 | $4.64M |
| Jun 30, 2019 | -$0.74 | -$0.86 | -$0.98 - $0.19 | +13.95% | Beat | N/A | 5 | N/A | Aug 8, 2019 | $2.16M |
| Mar 31, 2019 | -$0.29 | -$0.77 | -$0.85 - -$0.70 | +62.34% | Beat | N/A | 4 | N/A | May 9, 2019 | $7.72M |
| Dec 31, 2018 | -$0.60 | -$0.75 | -$0.96 - -$0.61 | +20.00% | Beat | N/A | 5 | N/A | Mar 14, 2019 | $1.69M |
| Sep 30, 2018 | -$0.60 | -$0.63 | -$0.73 - -$0.52 | +4.76% | Beat | N/A | 5 | N/A | Nov 8, 2018 | $658000 |
| Jun 30, 2018 | -$0.69 | -$0.77 | -$1.09 - -$0.15 | +10.39% | Beat | N/A | 6 | N/A | Aug 9, 2018 | $463000 |
| Mar 31, 2018 | -$0.74 | -$1.20 | -$1.67 - -$0.77 | +38.33% | Beat | N/A | 5 | N/A | Apr 2, 2018 | $1.15M |
| Sep 30, 2017 | -$36.02 | -$35.07 | N/A | -2.71% | Miss | N/A | N/A | N/A | Dec 14, 2017 | $597000 |
| Jun 30, 2017 | -$2.96 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 30, 2017 | $249000 |
| Mar 31, 2017 | -$0.51 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2017 | $140000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.12, a profit after a loss of $1.26 per share the year before. It was -$42.12 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.12 | N/A |
| Dec 31, 2024 | -$1.26 | -341.7% |
| Dec 31, 2023 | $0.52 | N/A |
| Dec 31, 2022 | -$1.22 | N/A |
| Dec 31, 2021 | -$2.89 | N/A |
| Dec 31, 2020 | -$3.58 | N/A |
| Dec 31, 2019 | -$3.34 | N/A |
| Dec 31, 2018 | -$42.12 | N/A |
Earnings Calls
The 3 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 3,300 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 3,273 | 5 | |
| 2025Q2 | Jun 30, 2025 | 1,806 | 6 | |
| 2024Q2 | Jun 30, 2024 | 3,326 | 8 |
2026Q2 Earnings Call
Opening remarks
Shai Biran Head of Investor Relations Thank you, operator, and thank you all for participating in today's conference call. This afternoon, Spero Therapeutics released financial results and provided a business update for the second quarter of 2026. A press release is available on the Investor page of the Spero Therapeutics website. Before we begin, I would like to remind you that some of the information presented on this conference call contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended. These forward-looking statements are based on Spero's current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties associated with our business and factors that could cause or contribute to such differences are described in Spero's filings with the Securities and Exchange Commission, including in the Risk Factors section of the earnings report on Form 10-Q for the quarter ended June 30, 2026, filed today. Leading the call today are Esther Rajavelu, our President and Chief Executive Officer; and Dr. Debra Zack, our Chief Medical Officer. There will be a Q&A session following the prepared remarks. I will now turn the call over to Esther to begin.
Esther Rajavelu President and Chief Executive Officer Thank you, Shai. Good afternoon, everyone, and thank you for joining us on our second quarter earnings and business update call. I will begin with key highlights from the quarter, outline our strategy and priorities going forward and then review our financial results. In the last 90 days, we had four major milestones. The FDA approved Utebzi, the first and only oral carbapenem for the treatment of complicated urinary tract infections, including pyelonephritis, which we developed with our licensing partner, GSK. We in-licensed SP001 and repositioned the company's pipeline to focus on immune-mediated diseases. We closed $105 million in nondilutive, nonrecourse financing, and we hired a Chief Medical Officer. Let me start with the last one by welcoming Dr. Debra Zack to the Spero team as our CMO. Deb is a board-certified rheumatologist with a PhD in immunology and extensive drug development experience spanning research, clinical development and medical affairs. She brings more than 25 years of leadership in developing therapeutics for immune-mediated diseases, most recently as CMO at Exagen and before that in clinical leadership roles at Amgen, Xencor and Novartis. She officially joined Spero as CMO on August 3 to lead our clinical development strategy as we advance SP001 into the clinic. Deb, welcome. We are so glad you're here and look forward to your comments on SP001 later during this call. Let me now turn to the quarter.
Frequently Asked Questions About SPRO
When is Spero Therapeutics's next earnings date?
Spero Therapeutics's next earnings report is expected for Mar 24, 2027.
Did SPRO beat earnings estimates last quarter?
No. Spero Therapeutics reported EPS of -$0.16 for the quarter ended Sep 30, 2026, below the -$0.14 estimate by 14.29%.
What EPS do analysts expect from SPRO next quarter?
The consensus EPS estimate for Spero Therapeutics for the quarter ending Dec 31, 2026 is -$0.21 from 4 analysts, with estimates from -$0.26 to -$0.15.
How often does SPRO beat earnings estimates?
Spero Therapeutics beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of +23.84%.
SPRO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts